What You Should Know:
– Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence, today announced a strategic partnership to accelerate precision medicine and expand the Immunology Multimodal Network, advancing shared decision making for patients with rheumatoid arthritis (RA).
– This collaboration will leverage Scipher’s unique data and intelligence derived from its PrismRA® precision medicine diagnostic and expand the Atropos Evidence™Network , enhancing the immunology multimodal network on Atropos Health’s GENEVA OS™(Generative Evidence Acceleration Operating System). Scipher’s PrismRA test identifies patients who are unlikely to respond to specific RA therapies, enabling personalized treatment decisions.
Advancing Precision Medicine in Rheumatoid Arthritis: PrismRA and Atropos Health Collaboration
PrismRA, a groundbreaking blood test, is revolutionizing the treatment of rheumatoid arthritis (RA), a condition affecting 20 million people globally. Through a simple blood draw, PrismRA analyzes an individual’s molecular signature to identify patients unlikely to respond adequately to TNFi therapy, the world’s top-selling drug class. This enables clinicians to prescribe more effective alternative therapies, minimizing unnecessary dose escalations or cycles of ineffective treatment.
In collaboration with Atropos Health, PrismRA’s molecular insights will be integrated into the Atropos Evidence Network, expanding access to advanced, AI-powered evidence generation tools such as Green Button and ChatRWD™—the first AI-driven chat-to-database application in healthcare. These tools deliver real-world evidence within minutes, empowering clinicians with actionable data to support shared decision-making.
The partnership underscores a significant advancement in precision medicine for rheumatology:
- Enhanced Decision-Making: Clinicians gain access to real-world evidence from a multimodal immunology network, enabling personalized care plans.
- Streamlined Evidence Generation: AI-powered tools like ChatRWD™ facilitate rapid evidence generation to inform treatment strategies.
- Improved Patient Outcomes: The collaboration prioritizes precision medicine, optimizing therapy selection and enhancing care for RA patients.
Reg Seeto, CEO of Scipher Medicine, highlighted the collaboration’s transformative potential: “By combining Scipher’s unique RA data assets with Atropos Health’s cutting-edge AI evidence generation tools, we are equipping clinicians with the resources needed to make informed treatment decisions and deliver personalized care.”
This strategic partnership represents a pivotal step in advancing precision medicine, with the ultimate goal of improving the lives of RA patients worldwide.
